Advances in Radiation Oncology in Lung Cancer by Dusan Milanovic (auth.), Branislav Jeremic (eds.)

By Dusan Milanovic (auth.), Branislav Jeremic (eds.)

Although many years of laboratory and scientific learn have ended in incremental development in remedy end result, lung melanoma is still the most lethal illnesses. within the moment, thoroughly up to date version of this complete publication, some of the world’s best lung melanoma experts talk about the hot advances within the radiation oncology of lung melanoma and think of the most recent examine findings. the 1st 3 sections hide the fundamental technology of lung melanoma, scientific investigations, together with histology and staging, and a variety of primary therapy concerns. present therapy innovations for nonsmall mobile and small cellphone lung melanoma are then defined and evaluated intimately, with due consciousness to novel techniques that promise extra advancements in final result. many of the kinds of treatment-related toxicity are mentioned, and caliber of existence reports and prognostic elements also are thought of. After comparing the newest technological and organic advances, together with IMRT, IMAT, cyber knife therapy, and tomotherapy, the booklet concludes by way of thorough attention of particular points of medical learn in lung melanoma.

Show description

Read Online or Download Advances in Radiation Oncology in Lung Cancer PDF

Best oncology books

Intraperitoneal Therapy for Ovarian Cancer

Intraperitoneal chemotherapy is more and more getting used as first-line therapy for ovarian melanoma. however, it truly is tricky for the oncologist to discover a definitive textual content that files either the elemental equipment required to optimize treatment and the up to date result of section I, II, and III medical trials.

L'adolescent atteint de cancer et les siens: Quelle détresse, quelles difficultés, quels souhaits d'aide? (French Edition)

Les auteurs présentent les données théoriques sur l’adolescence, le melanoma, los angeles verbal exchange intrafamiliale et les résultats pragmatiques issus de deux études, belge, de l’Institut Jules Bordet et française, de l’Institut Gustave Roussy, sur l. a. détresse et les besoins des young people atteints de melanoma.

Handbook of Gynaecologic Oncology

A instruction manual of gynaecologic oncology, providing a complete yet concise consultant to the treatment of gynaecologic melanoma. Edited and written by means of the school of the gynaecologic programmes of MD Anderson melanoma middle and Memorial Sloan-Kettering melanoma heart, it's designed to be a advisor to the analysis and remedy of gynaecologic melanoma, however it additionally positive aspects chapters on breast and colon cancers.

Thoracic Oncology

Within the usa by myself, the occurrence of latest situations of thoracic neoplasms is over 180,000. every year, over 170,000 everyone is anticipated to die in their melanoma. Lung melanoma is the most typical of the thoracic neoplasms. it's the top explanation for melanoma dying in either women and men, accounting for 28% of all melanoma deaths within the usa.

Additional resources for Advances in Radiation Oncology in Lung Cancer

Sample text

W. Siemann Table 1 Endogenous regulatory factors involved in angiogenesis Pro-angiogenic Factors Anti-angiogenic Factors Vascular endothelial growth factor (VEGF-A, B, C, D, E) Angiostatin Placental growth factor Endostatin Platelet-derived growth factor (PDGF) Vasostatin Basic fibroblast growth factor (bFGF/FGF-2) Thrombospondin-1 and internal fragment Acidic fibroblast growth factor (aFGF/FGF-1) Vascular endothelial growth factor inhibitor Fibroblast growth factor-3 (FGF-3/int-2) Fragment of platelet factor-4 Fibroblast growth factor-4 (FGF-4/hst/K-FGF) Derivative of prolactin Hepatocyte growth factor/Scatter factor (HGF/SF) Restin Transforming growth factor-a (TGF-a) Proliferin-related protein Transforming growth factor-b (TGF-b) SPARC cleavage product Tumor necrosis factor-a (TNF-a) Osteopontin cleavage product Granulocyte colony stimulating factor Interferon-a, Interferon-b Interleukin-8 METH-1, METH-2 Pleiotropin Angiopoietin-2 Angiogenin Antithrombin III fragment Proliferin Interferon-inducible protein-10 Matrix metalloproteinases (MMPs) Tissue inhibitors of metalloproteinases (TIMPs) Angiopoietin-2 Prolactin Prostaglandin E1 and E2 Interleukin 1, 6, 12 Thymidine phosphorylase (TP) VEGF soluble receptor Platelet-derived endothelial cell growth factor (PD-ECGF) Dll4 Intergrin Ephrin Typically, angiogenesis in tumors has been assessed indirectly by determining intratumoral microvessel density (MVD).

Still, survival in patients with lung cancer remains poor. The 5 year survival rate for all stages combined is only 5–15% (Comis 2003; Kepka et al. 2009). The majority of patients die from disease progression locally, at distant sites, or both. Pathologic staging, which incorporates factors such as tumor size and grade, nodal status and presence or absence of distant metastases, provides the best prediction of treatment outcome (Mountain 2000; Beadsmoore and Screaton 2003). However, because the growth of primary tumors and metastases is angiogenesis dependent (Folkman 1971, 2002), a great deal of attention has recently been paid to the role of this process not only in lung cancer formation, progression, and prognosis, but also in the development of novel therapeutic strategies for this disease.

5 or 15 mg/kg. The patients continued bevacizumab or placebo as maintenance until progression (Reck et al. 2009). 1 months in placebo group. There was no significant difference in overall survival between groups. 5 mg/ kg) of bevacizumab yielded similar efficacy and safety profile. The regimen was overall well tolerated. 9% for chemotherapy alone group (Reck et al. 2009). A recent meta-analysis evaluated the efficacy of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated locally advanced or metastatic NSCLC (Botrel et al.

Download PDF sample

Rated 4.10 of 5 – based on 23 votes